Summary of evidence and Expert Committee recommendations

The Subcommittee accepted that medicines affecting coagulation were essential for children and endorsed phytomenadione for inclusion in the EMLc. As phytomenadione is routinely administered to neonates, the Subcommittee decided this medicine should be included in the Core List and recommended the addition of phytomenadione injection 1 mg/ml to the list.